Patents by Inventor Zhiwei Yin

Zhiwei Yin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridines as inhibitors of human immunodeficiency virus replication
    Patent number: 10189816
    Abstract: Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: January 29, 2019
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Kyle J. Eastman, John F. Kadow, Kyle E. Parcella, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Benzofurans substituted with primary benzamide as HCV inhibitors
    Patent number: 10131645
    Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: November 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • Benzofuran compounds for the treatment of hepatitis C
    Patent number: 10125111
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus, (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: November 13, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John F. Kadow
  • Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors
    Patent number: 10125137
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV: Formula (I).
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: November 13, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • Benzofurans substituted with secondary benzamide as HCV inhibitors
    Patent number: 10087167
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 2, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • 5-(N-FUSED TRICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180230134
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Inventors: John F. KADOW, B. Narasimhutu NAIDU, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • 5-(N-BENZYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180230129
    Abstract: Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Inventors: Kyle J. EASTMAN, John F. KADOW, Kyle E. PARCELLA, B. Narasimhulu NAIDU, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • 5-(N-[6,5]-FUSED BICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180222890
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 9, 2018
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180170903
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: July 6, 2016
    Publication date: June 21, 2018
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Tao WANG, Zhiwei YIN
  • BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS
    Publication number: 20180099953
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV.
    Type: Application
    Filed: February 17, 2016
    Publication date: April 12, 2018
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • Ammonium derivatives for the treatment of hepatitis C
    Patent number: 9918988
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: March 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Paul Michael Scola
  • Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C
    Patent number: 9920036
    Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: (I).
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: March 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • SUBSTITUTED BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20180030019
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Application
    Filed: February 17, 2016
    Publication date: February 1, 2018
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • BENZOFURANS SUBSTITUTED WITH BICYCLIC SECONDARY BENZAMIDE AS HCV INHIBITORS
    Publication number: 20180030056
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Application
    Filed: February 17, 2016
    Publication date: February 1, 2018
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS
    Publication number: 20180030017
    Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Application
    Filed: February 17, 2016
    Publication date: February 1, 2018
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20180030016
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Application
    Filed: February 17, 2016
    Publication date: February 1, 2018
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John F. Kadow
  • Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 9834566
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: December 5, 2017
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Compounds for the treatment of hepatitis C
    Patent number: 9745322
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: August 29, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Paul Michael Scola
  • CYANOAMINO (AZA)BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170174667
    Abstract: Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 22, 2017
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • Guanidine derivatives for the treatment of hepatitis C
    Patent number: 9655902
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: May 23, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Ying Han, Zhiwei Yin, Paul Michael Scola